Actividad científica: Publicaciones

2017
  1. Association of DDX58 177 C > T polymorphism with decreased risk of Epstein-Barr virus-related nodular sclerosis classical Hodgkin lymphoma.
    Martin P, Martínez-Velasquez J, Coronado MJ, Krsnik I, Provencio M, Navarro B, Moraru M, Bellas C, Vilches C, Gomez-Lozano N. Leuk Lymphoma 2017; 58:438-444.
  2. mRNA in exosomas as a liquid biopsy in non-Hodgkin Lymphoma: a multicentric study by the Spanish lymphoma oncology group.
    Mariano Provencio, Marta Rodríguez, Blanca Cantos, Pilar Sabín, Cristina Quero, Francisco R. García-Arroyo, Antonio Rueda, Constanza Maximiano, Delvys Rodríguez-Abreu, Antonio Sánchez, Javier Silva, Vanesa García, on behalf of GOTEL (Spanish Lymphoma Oncology Group). Oncotarget, 2017 (article in press).
2016
  1. Survival in young adults diagnosed with follicular lymphoma.
    Calvo V, Provencio M, Gómez Codina J, Rodríguez Abreu D, Rueda A. Ann Oncol 2016; 27:751.
  2. Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma.
    Almagro-Casado E, Sánchez A, Cantos B, Salas C, Pérez-Callejo D, Provencio M. Clin Transl Oncol 2016; 18:99-106.
  3. Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group
    F. Franco, J. Lavernia, D. Aguiar-Bujanda, J. Miramón, J. Gumá, R. Álvarez, J. Gómez-Codina, F. García Arroyo, M. Llanos, M. Marin Vera, J. Alfaro, C. Quero, M. Delgado, E. Nogales, F. Menarguez, M. Martinez, M. Torrente, M. Royuela, D. Abreu, M. Provencio. Clinical Lymphoma, Myeloma and Leukemia (in press, 2016)
2015
  1. Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma?
    Rubio J, Franco F, Sánchez A, Cantos B, Méndez M, Calvo V, Maximiano C, Perez D, Millán I, Sánchez-Beato M, Provencio M. Leuk Lymphoma 2015; 56: 1686-90.
  2. A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma.
    Rueda A, García-Sanz R, Pastor M, Salar A, Labrador J, Quero-Blanco C, Casanova M, Provencio M; Gotel and Geltamo. Acta Oncol 2015; 54: 933-8.
  1. Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas.
    Pérez-Callejo D, González-Rincón J, Sánchez A, Provencio M, Sánchez-Beato M. Cancer Treat Rev 2015; 41: 680-9.
  1. HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01/*02.
    Martín P, Krsnik I, Navarro B, Provencio M, García JF, Bellas C, Vilches C, Gomez-Lozano N. PLoS One 2015; 11;10(8):e0135512.
  1. High-dose chemotherapy followed by autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular non-Hodgkin’s lymphoma in the rituximab era.
    Escobar IG, Sánchez de Ibarguen BC, de Juan VC, Alonso CM, García MM, Ruíz AC, Pulla MP. Tumori 2015; 101: 2-7.
  1. Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas.
    Manso R, Rodríguez-Pinilla SM, González-Rincón J, Gómez S, Monsalvo S, Llamas P, Rojo F, Pérez-Callejo D, Cereceda L, Limeres MA, Maeso C, Ferrando L, Pérez-Seoane C, Rodríguez G, Arrinda JM, García-Bragado F, Franco R, Rodriguez-Peralto JL, González-Carreró J, Martín-Dávila F, Piris MA, Sánchez-Beato M. Haematologica 2015; 100:e25-7.
  1. Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T cell lymphoma.
    Pérez C, González-Rincón J, Onaindia A, Almaráz C, García-Díaz N, Pisonero H, Curiel-Olmo S, Gómez S, Cereceda L, Madureira R, Hospital M, Suárez-Massa D, Rodriguez-Peralto JL, Postigo C C, Leon-Castillo A, González-Vela C, Martínez N, Ortiz-Romero P, Sánchez-Beato M, Piris MÁ, Vaqué JP. Haematologica 2015 Nov;100(11):e450-3. doi: 10.3324/haematol.2015.132837.
  1. SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma.
    Provencio Pulla M, Alfaro Lizaso J, de la Cruz Merino L, Gumá I Padró J, Quero Blanco C, Gómez Codina J, Llanos Muñoz M, Martinez Banaclocha N, Rodriguez Abreu D, Rueda Domínguez A.  Clin Transl Oncol. 2015 Dec;17(12):1014-9. doi: 10.1007/s12094-015-1437-1.
  1. SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma.
    Rueda Domínguez A, Alfaro Lizaso J, de la Cruz Merino L, Gumá I Padró J, Quero Blanco C, Gómez Codina J, Llanos Muñoz M, Martinez Banaclocha N, Rodriguez Abreu D, Provencio Pulla M. Clin Transl Oncol. 2015 Dec;17(12):1005-13. doi: 10.1007/s12094-015-1429-1.
2013 - 2014
  • Montes-Moreno S, Batlle A, de Villambrosía SG, Sánchez-Espiridión B, Cereceda L, González-Barca E, Purroy N, Pardal E, Martín A, Grande C, Mazorra F, Insunza A, Quero C, Aguiar D, Cruz MA,Rueda A, Llanos M, Codina JG, Arroyo FR, Caballero D, Conde E, López A, Provencio M, Piris M. Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis. Haematologica 2014; 99(8):e138-41.
  • Rubio J, Franco F, Sánchez A, Cantos B, Méndez M, Calvo V, Maximiano C, Perez D, Millán I, Sánchez-Beato M, Provencio M. Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma? Leuk Lymphoma 2014 Nov 20:1-5. [Epub ahead of print]
  • Rueda A, Olmos D, Vicioso L, Quero C, Gallego E, Pajares-Hachero BI, Mendiola M, Casanova M, Alvarez M, Provencio M, Alba E. Role of vascular endothelial growth factor C in classical c. Leuk Lymphoma 2014; 7:1-26. [Epub ahead of print]
  • Rueda A, Rifá J, Quero C, Gómez-Codina J, Murias A, García-Arroyo FR, Sabín P, Llanos M, Herrero J, Lobo F, Delgado JR, Provencio M; on behalf of the Spanish Lymphoma Oncology Group. High serum levels of VEGF-C have a positive impact on outcome of advanced diffuse large B cell lymphoma patients. Leuk Lymphoma 2014; 55: 1413-6
  • Provencio M, Cruz Mora MA, Gómez Codina J, Quero Blanco C, Llanos M, García Arroyo FR, De la Cruz L, Gumá Padró J, Delgado Pérez JR, Sánchez A, Alvarez Cabellos R, Rueda A; On behalf of the GOTEL (Spanish Lymphoma Oncology Group). Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after a new induction regimen in intermediate and high-risk follicular lymphoma patients according to the follicular lymphoma international prognostic index (FLIPI): A multicenter, prospective Phase II trial of Spanish Lymphoma Oncology Group. Leuk Lymphoma 2014; 55: 51-5.
  • Provencio M, Sanchez A, Sánchez-Beato M. New drugs and targeted treatments in Hodgkin’s Lymphoma. Cancer Treat Rev 2014; 40: 457-64.
  • David Aguiar-Bujanda, María Jesús Blanco-Sánchez, Pedro Jiménez-Gallego, Marta Mori-De Santiago, María Hernández-Sosa, Saray Galván-Ruíz, Samuel Hernández-Sarmiento, Salvador Saura-Grau & Uriel Bohn-Sarmiento. Therapeutic approaches in patients with newly diagnosed follicular lymphoma.. Future Oncology 2014; 10: 1967-80.
  • David Aguiar-Bujanda, Ignacio Llorca-Mártinez, José C. Rivero-Vera, María J. Blanco-Sánchez, Pedro Jiménez-Gallego, Marta Mori-De Santiago, Miguel A. Limeres-Gonzalez, José C. Cabrera-Marrero, María Hernández-Sosa, Saray Galván-Ruíz, Samuel Hernández-Sarmiento, Salvador Saura Grau and Uriel Bohn-Sarmiento Hematological Oncology. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.. Hematol Oncol 2014; 32: 139–144.
2012

 

1. Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain?

Mariano Provencio, Pilar Sabín, José Gómez Codina, Antonio Rueda, Marta Llanos, Josep Gumá, Cristina Quero Blanco, Ana Blasco, Juan Ramón Delgado, Miguel Ángel Cruz, David Aguiar, Fco Ramón García-Arroyo, Joaquín Herrero, Javier Lavernia, Natividad Martínez Banaclocha, Manuel Morales, José Fuster, Alvaro Sáez Cusi, Fco Lobo, Delvys Rodríguez Abreu, Luis de la Cruz, Edelmira Antón, Alberto Rodríguez Jiménez, Alberto Arízcun, Xavi Pérez.Clin Trans Oncol 2012;14:386-90

 

2. Has the time to come leave the “watch-and-wait” strategy in newly diagnosed asymptomatic follicular lymphoma patients?

Rueda A, Casanova M, Redondo M, Pérez-Ruiz E, Medina-Pérez A. BMC Cancer 2012; 12:210.

 

3. Role of immune escape mechanisms in Hodgkin’s lymphoma development and progression: a whole new world with therapeutic implications.

de la Cruz-Merino L, Lejeune M, Nogales Fernández E, Henao Carrasco F, Grueso López A, Illescas Vacas A, Pulla MP, Callau C, Álvaro T. Clin Dev Immunol. 2012;2012:756353.

2011

1. López-Guillermo A, Caballero D, Canales M, Provencio M, Rueda A, Salar A; Spanish Hematology and Hemotherapy Association; Oncological Group for the Treatment of Lymphatic Diseases; Spanish Lymphomas/Autologous Bone Marrow Transplant Group. Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma. Leuk Lymphoma 2011; 52:1-14

 

2. Critical appraisal of pralatrexate in the  management of difficult-to-treat peripheral T cell lymphoma. Casanova M, Medina-Pérez A, Moreno-Beltran M, Mata-Vazquez M, Rueda A. Ther Clin Risk Manag 2011; 7:401-8.

 

3. Heterogeneous expresión of Src tyrosine kinases Lyn, Fyn, and Syk in classical Hodgkin lymphoma: prognostic implications. Paloma Matrtin, Clara Salas, Mariano Provencio, Victor Abraira, Carmen Bellas. Leukemia and Lymphoma, 2011. (F.I.: 2,49)

 

4. Epstein-Barr virus in the germinal centres of adenopathies affected by classic Hodgkin Lymphoma. P Martin, N Gómez-Lozano, S Montes, C Salas, M Provencio, C Bellas. Histopathology 2011; 59(2): 349-52.(F.I:: )

 

5. Breast Cancer occurred after Hodgkin´s disease: clinico-pathological features, treatments and outcome: Analysis of 214 cases. Cutuli B, Kanoun S, Tunon De Lara C, Baron M, Livi L, Levy C, Cohen-Solal-Lenir C, Lesur A, Kerbrat P, Provencio M, Gonzague-Casabianca L, Mege A, Lemanski C, Delva C, Lancrenon S, Velten M. Crit Rev Oncol Hematol. 2011 Feb 16. (F.I.: 5,269)

 

2010

1. SEOM clinical guidelines for the treatment of diffuse large B-cell lymphoma.

Gómez-Codina J, Sabín Dominguez P, Provencio M, Rueda A, Isla DM.

Clin Transl Oncol 2010; 12 (11): 765-9. (FI: 1,1)

 

  1.  SEOM clinical guidelines for the treatment of follicular non-Hodgkin´s lymphoma.

Rodríguez-Abreu D, Llanos M, Provencio M, Rueda A, Isla MD. Clin Transl Oncol 2010; 12 (11): 760-4 (FI: 1,1)

 

  1.  SEOM Clincal guidelines for the treatment of Hodgkin´s lymphoma.

Quero Blanco C, García Arroyo R, Provencio M, Rueda A, Isla MD.

Clin Transl Oncol 2010; 12 (11): 753-9. (FI:1,1).

 

  1.  Late relapses in Hodgkin’s disease: a clinical and molecular study.  

Provencio M,  Salas C,  Millán I,  Cantos B,  Sánchez A,  Bellas C. Leukemia & Lymphoma 2010, sep ; 51 (9): 1686-91. (FI:2,39)

 

  1.  Caspase-3a: new prognostic marker for diffuse large b-cel lymphoma in the post-rituximab era.  

Provencio M,   Candia A,  Martín P,   García V,  .Sánchez AC,  Bellas B. Leukemia & Lymphoma 2010, Oct 4. (F.I.:2,39)

 

  1.  Tumor Microenvironment and Immune Effects of Antineoplastic Therapy in Lymphoproliferative Syndromes.

Álvaro T,  de la Cruz-Merino L,  Henao-Carrasco F,  Villar Rodríguez JL,  Vicente Baz D,  Codes  M, de Villena M,  Provencio M. Journal of Biomedicine and Biotechnology 2010 pii: 846872.  (FI: 1,86)

 

  1.  Clinical significance of occult cerebrospinal fluid involvement assesed by flow cytometry in non-hodgkin´s lymphoma patients at high-risk of central nervous system disease in the rituximab era.

Sancho JM, Orfao A, Quijano S, García O, Panizo C, Pérez-Ceballos E, Deben G, Salar A, González-Barca E, Alonso N, García-Vela JA, Capote J, Peñalver FJ, Provencio M, Arias J, Plaza J, Caballero D, Morado M, Feliu E, Ribera JM; (For the Spanish Group for the Study of CNS Disease in NHL). Eur J Haematol. 2010, oct; 85(4): 321-8 (FI: 2,32)

 

  1.  Central nervous system involvement in Hodgkin´s lymphoma.

Galán L, Sánchez AC, Cantos B, Provencio M. Med Oncol 2010; oct 14 (F.I:: 1,22)

 

  1.  Therapeutic management of chronic lymphocitic leukemia. State of the art and future perspectives. García-Escobar I, Sepúlveda J, Castellano D, Cortés-Funes H. Crit Rev Oncol Hematol. 2010 Dec 9.

 

10. Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab.

Maximiano C,  Sánchez AC,  Cantos B ,  Méndez M,  Provencio M. Clinical Translation Oncology 2010;12: 701-703. (FI: 1,1)

 

11. Rituximab monotherapy in relapsed lymphocyte-predominant hodgkin’s  lymphoma.

Galán L,  Sánchez AC,  Cantos B,  Provencio M. Clinical Translation Oncology 2010; 12 (5): 384-6. (FI: 1,1)

 

2009
  1.  Differential genetic and functional markers of second neoplasias in Hodgkin’s disease patients.

Lorenzo Y, Provencio M, Lombardía L, Díaz R, Silva J, Herrera M, García JM, Peña C, García V, Romero J, Domínguez G, Bonilla F. Clin Cancer Res. 2009 Aug 1;15(15):4823-8

 

  1.  A TaqMan low-density array to predict outcome in advanced Hodgkin’s lymphoma using paraffin-embedded samples.

Sánchez-Espiridión B, Sánchez-Aguilera A, Montalbán C, Martin C, Martinez R, González-Carrero J, Poderos C, Bellas C, Fresno MF, Morante C, Mestre MJ, Mendez M, Mazorra F, Conde E, Castaño A, Sánchez-Godoy P, Tomas JF, Morente MM, Piris MA, García JF; Spanish Hodgkin’s Lymphoma Study Group. Clin Cancer Res. 2009 Feb 15;15(4):1367-75.

 

  1.  A prospective study of left ventricle function after treatment with rapid-infusion rituximab in non-hodgkin lymphoma patients.

Provencio M, A Sánchez, Maximiano C, Cantos, Méndez M, Bonilla F.  Leukemia and Lymphoma, 2009.

 

  1.  Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications.

Garcia V, Garcia JM, Silva J, Martin P, Peña C, Dominguez G, Diaz R, Herrera M, Maximiano C, Sabin P, Rueda A, Cruz MA, Rodriguez J, Canales MA, Bonilla F, Provencio M. PLoS One. 2009 Dec 15;4(12):e8173.

 

  1.  Rescue treatment with bendamustine in patients with diffuse large B-cell lymphoma.

M Huelves, AC Sánchez, S Mellor, M Provencio. Cancer Therapy 2009; 7: 488-490

 

  1.  Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients.

Carrato A, Paz-Ares Rodríguez L, Rodríguez Lescure A, Casas Fernández de Tejerina AM, Díaz Rubio García E, Pérez Segura P, Constenla Figueiras M, García Carbonero R, Gómez Codina J, Lluch Hernández A, Maroto Rey JP, Martín Jiménez M, Mayordomo Cámara JI, Moreno Nogueira JA, Rueda Domínguez A; Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol. 2009 Jul;11(7):446-54.

 

  1.  Mantle cell lymphoma stage IV affecting lacrimal glands, retro-orbital tissue, optic nerve and ocular motor muscles.

Pajares-Hachero B, Torres E, Hierro I, Jurado JM, Rueda A. Clin Transl Oncol. 2009 Jul;11(7):484-5.

 

  1.  Capítulo del libro TRATADO DE ONCOLOGIA. Editorial Publicaciones Permanyer, 2009. ISBN 978-84-92620-16-6. Tomo II. Mieloma múltiple, 645-674.

García Arroyo FR.

 

9. Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma. Clin Transl Oncol. 2009 Sep;11(9):604-8.

Aguiar Bujanda D, Aguiar Morales J, Bohn Sarmiento U, Saura Grau S, Rodríguez Franco C.

2008

1. R-CHOP-14 in patients with diffusse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. Hematological Oncol. 2008;26(1):27-32.

Rueda A, Sabin P, Rifá J, Llanos M, Gómez-Codina J, Lobo F, García R, Herrero J, Provencio M, Jara C

2. Quimioterapia intensiva y de rescate con progenitores hematopoyéticos autólogos en el tratamiento de los linfomas no hodgkinianos. Med Clin (Barc). 2008;130(2):60-65

Provencio M, Fayad LE

3. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579-86.

Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G.

4. Analysis of competing risks of causes of death and their variation over different time periods in Hodgkin’s disease. Clin Cancer Res. 2008;14(16):5300-5.

Provencio M, Millán I, España P, Sánchez AC, Sánchez JJ, Cantos B, Vargas JA, Bellas C, García V, Sabin P, Bonilla F.

5. GESIDA/PETHEMA guidelines for the diagnosis and treatment of lymphomas in HIV-infected patients. Med Clin (Barc). 2008;130(8):300-11.

Miralles P, Berenguer J, Ribera Santasusana JM, Calvo F, Díaz Mediavilla J, Díez-Martín JL, Gómez-Codina J, López Aldeguer J, Rubio R, Santos J, Valencia E.

6. Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin’s lymphoma in Spain. Med Clin (Barc). 2008;131(12):441-6.

Sancho JM, Morgades M, Alonso N, Deben G, Fernández de Sevilla A, Vázquez L, Nicolás C, García Vela JA, Arranz R, Abella E, Canales MA, Miralles P, Sánchez E, Hermosilla M, Conde E, Rueda A , Ribera JM; investigators of QUIT Study (PETHEMA, GELTAMO and GOTEL Groups).

González-Barca E, Domingo-Domenech E, Capote FJ, Gómez-Codina J, Salar A, Bailen A, Ribera JM, López A, Briones J, Muñoz A, Encuentra M, de Sevilla AF; GEL/TAMO (Grupo Español de Linfomas); GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear); GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas)

7. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab.Ann Oncol. 2008 Feb;19(2):396-7.

Aguiar Bujanda D.

2007

1. Presentation of Hodgkin´s lymphoma with Ophelia Syndrome. J Clin Oncol 2007: 25: 1802-1803.
Olmos D, Rueda A, Jurado JM, Alba E.

2. Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission.Clin Lymphoma Myeloma 2007; 7: 400-5.
Rueda A, Olmos D, Villarreal V, Torres E, Pajares BI, Alba E

3. Prospective phase II trial of extended treatment with rituximab in patients with B-cell pos-transplant lymphoproliferative disease. Haematologica. 2007; 92:1489-94.

González-Barca E, Domingo-Domenech E, Capote FJ, Gómez-Codina J, Salar A, Bailen A, Ribera JM, López A, Briones J, Muñoz A, Encuentra M, de Sevilla AF; GEL/TAMO (Grupo Español de Linfomas); GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear); GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas)

4. Primary duodenal follicular lymphoma successfully treated with rituximab. Aguiar-Bujanda D, Quiñones-Morales I, Camacho-Galán R, Llorca-Martínez I, Rivero-Vera JC, Bohn-Sarmiento U, Aguiar-Morales J. Clin Transl Oncol. 2007 Jul;9(7):471-2

2006

1. Association between virus C and non-Hodgkin Lymphoma.
Provencio M, Sánchez A; Bonilla F, España P.  J Clin Oncol 2006 Jul 20; 24(21): 3513

2. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classical Hodgkin lymphoma.
Sánchez Aguilera A, Montalbán C, De la cueva P, Sánchez Verde L, Morente MM; García Cosio M, Garcia Laraña J, Bellas C, Provencio M, Romagosa V, Fernadez Sevilla A, Menarguez J, Sabin P, Mestre MJ, Mendez M, Fresno MF, Nicolas C, Piris MA, García JF. Blood 2006 Mar 21.

3. Rapid-infusión Rituximab in lymphoma treatment.
Provencio M,  Cerdeira S, Sánchez A; Bonilla F, España P. Ann  Oncol 2006, Jun, 17 (6): 1027-8.

4. Linfoma no hodgkin difuso de células grandes B en estadios avanzados: situación del tratamiento actual y perspectivas.
M Provencio, A Rueda, P Sabín. Oncología 2006; 29: (10):11-13

5. An Uncommon Presentation Of Non-Hodgkin´s Lymphoma: Diffuse Large-Cell Lymphoma Presenting As A Peritoneal Mass. Leukemia & Lymphoma 2006; 47: 933-934.
Olmos D, Rueda A, Torres E, Viciana R, Vicioso L, Alba E.

6. Treatment for relapse in stage I /II Hodgkin’s disease after initial single-modality treatment. Clin Lymphoma & Myeloma 2006; 6: 389-392.
Rueda A, Olmos D, Viciana R, Alba E.

7. Rituximab maintenance therapy in follicular lymphoma. Cancer & Chemotherapy Reviews 2006; 1: 99-106.
Rueda A, Olmos D, Medina A, Jurado JM.

8. Primary cutaneous marginal zone B-cell lymphoma (PCMZL-MALT). Bohn-Sarmiento U, Aguiar-Bujanda D, Aguiar-Morales J, Cabrera-Suárez MA. Clin Transl Oncol.2006 Jul;8(7):542-3.

9. Primary Hodgkin’s lymphoma of the caecum.Bohn-Sarmiento U, Rivero-Vera JC, Aguiar-Bujanda D, Cabrera Santana MA, Aguiar-Morales J. Clin Transl Oncol. 2006 Jun;8(6):450-2.

2005

1. Linfomas de muy alta agresividad.
García Arroyo FR, Palacios Ozores P, Constenla Figueiras M. En: Linfomas, Monografías de Oncología Médica 2005. Editor: Moreno Nogueira JA. Ed. You & Us SA, 2005; 93-135

2. Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis. Clin Transl Oncol. 2005 Jul;7(6):232-8. Rueda Domínguez A, Olmos Hidalgo D, Viciana Garrido R, Torres Sánchez E.

2004

1. Prognostic factors in Hodgkin´s disease.
M Provencio, P España, I Millan, et al. Leukemia & Lymphoma 45: 1133-1139, 2004

2. Gemcitabine in multi-resistant non-hodgkin lymphomas.
E Carcereny, P España, M Provencio. Tumori 90: 360-361, 2004

3. Influence of biologic markers on the outcome of Hodgkin’s lymphoma: a study by the Spanish Hodgkin’s lymphoma study group.
Journal Clinical Oncology 2004; 22: 1664-1673. Montalbán C, García JF, Abraira V; González-Camacho L, Morente M, Bello JL, Conde E, Cruz MA, García-Sanz R, García-Laraña J, Grande C, Llanos  M, Martínez R, Flores E, Méndez M, Ponderós C, Rayón C, Sánchez-Godoy P, Zamora J, Piris MA.

4. Treatment of stage I and II Hodgkin’s lymphoma with ABVD chemotherapy: results after 7 years of a prospective study.
Annals of Oncology 2004; 15: 1789-1804. Rueda Domínguez A, Márquez A, Gumá J, Llanos M, Herrero J, de las Nieves MA, Miramón J, Alba E.

5. Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: relationship to platelet alpha-granule content and primary activation. Int J Biol Markers 2004; 19: 221-8.
González FJ, Rueda A, Sevilla I, Alonso L, Villarreal V, Torres E, Alba E.

6. Treatment of stage I and II Hodgkin’s lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol. 2004 Dec;15(12):1798-804.
Rueda Dominguez A, Marquez A, Guma J, Llanos M, Herrero J, de Las Nieves MA, Miramon J, Alba E.

7. Intensive therapy for aggressive lymphoma. Aguiar Bujanda D, Bohn Sarmiento U, Aguiar Morales J. N Engl J Med. 2004 Jul 1;351(1):98-100

2003
ACTIVIDAD CIENTIFICA  » Publicaciones
 Publicaciones 2003

1. The topoisomerase II alplha expression correlates with survival patients with advanced Hodgkin’s lymphoma.
M Provencio, C. Corbacho, C Salas et al. Clin Cancer Res  (4): 1406-1, 2003.

2. The management of stage I-II supradiaphragmatic Hodgkin´s disease with chemotherapy alone.
M Provencio, P España, I Millán, A Sánchez, B Cantos, F Bonilla. Leukemia and Lymphoma, 44(2), 263-268, 2003.

3. Re: The topoisomerase IIa expresión correlates with survival in patients with advanced Hodgkin´s lymphoma.
M Provencio, P España, F Bonilla, C Salas. Clin Cancer Res 9: 5430-5431, 2003.

4. Patterns of outcome and prognostic factors in primary large cell lymphoma of the testis im a survey by the International Extranodal Lymphoma Study Group.
E Zucca, A Conconi, AH Sarris, Jf Seymour, M Provencio et al. J Clin Oncol 21: 20-27, 2003.

5. Linfomas asociados a SIDA. Revisiones en cáncer 2003; 17: 1-7.
M Llanos Muñoz, N Batista López, B Alonso Álvarez.

2001
1. Breast cancer ocurred after treatment for Hodgkin´s disease: analysis of 133 cases.
B Cutuli, C Borel, F Dhermain, SM Magrini, TH Wassermann, JA Bogart , M Provencio, et al. Radiation Oncology 2001 jun; 59(3):247-55.

2. Prevalencia de infección por el virus de la hepatitis C en pacientes con linfomas no Hodgkinianos.
AC Sánchez Ruiz, M Yebra, F Portero, M Provencio, C Miralles, P España. Medicina Clinica 2001; 116: 333-334.

3. Hodgkin´s disease: unsuspected minimal activity in patients that die form causes other than tumoral progression.
Provencio M, España P, et al. Leukemia-Lymphoma, 2001, vol. 42(4), pp 661-664.

4. Increase in the incidence of non-Hodgkin’s lymphoma, clinical features and long-term follow-up. Rev Oncología 2001; 3: 85-90.
M Llanos Muñoz, Remedios Alemán Valls, Hugo Álvarez-Argüelles Cabrera, Francisco Cáceres Gómez, Juana Oramas Rodríguez, Josefina Cruz Jurado, Manuel Morales González, Javier Dorta Delgado, Norberto Batista López.

5. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Medical Oncology 2001; 18 (1): 15-22.
M Llanos, H Alvarez-Argüelles, R Alemán, J Oramas, L Díaz-Flores, N Batista.

6. Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin´s lymphoma with ABVD. Leuk Lymphoma 2001; 41: 353-358.
Rueda A, Sevilla I, Gumá J, Ribelles N, Miramón J, de las Nieves MA, et al.

7. Granulocyte colony-stimulating factor (G-CSF) in the treatment of high-risk febrile neutropenia: A multicenter randomized trial. J Natl Cancer Inst 2001; 93: 31-38.
García-Carbonero R, Mayordomo JI, Tornamira M, Lopez-Brea M, Rueda A, Gillem V, et al.

2000 y anteriores
1. Hodgkin´s disease: correlation betwen causes of death at autopsy and clinical diagnosis.
Provencio M, España P, Salas C, et al. Annals of Oncolgy 11: 59-64, 2000.

2. Varón de 46 años con LNH folicular y recidiva tras remisión completa.
García Arroyo FR; Constenla M; Lorenzo I; Rey C; Carrete N. En: Casos Clínicos. Volumen II. Coordinador: Roche Oncology. Editorial Bates Healthworld, 2000

3. Comparision of long-term mortality in Hodgkin´s disease with the general population.
M Provencio, FJ García-López, et al. Annals of Oncology, 10: 1199-1205, 1999.

4. Linfomas no Hodgkin en las islas de La Palma, La Gomera y El Hierro.
Estudios Canarios, anuario del Instituto de Estudios Canarios 1999; 140-147.
Marta Llanos Muñoz, Remedios Alemán Valls, Javier Dorta Delgado, Norberto Batista López.

5. La Quimioterapia de Intensificación.
I Lorenzo; FR García Arroyo; M Constenla Figueiras. En: Guía de Presentaciones en Oncología Médica. Volumen V. Capítulo 22. Coordinadores: E Aranda y E Díaz Rubio, 1999

6. Anorectal Hodgkin disease in an HIV-infected patient. Med Clin (Barc) 1999, 112: 598-599.
Marquez-Moreno AJ, Rubio-Garrido J, Rueda-Domínguez A, Blanes-Berenguel A.

7. Infiltration of the central nervous system as a presentation form of early chronic lymphocyte leukemia. Am J Hematol 1998, 58: 339-340.
Perez Fernandez I, Salgado Ordoñez F, Rueda Domínguez A, Sevilla García I, Siles Rodríguez A.

8. Six Cycles of ABVD in the treatment of stage I and II Hodgkin´s lymphoma: a pilot study. J Clin Oncol 1997, 15: 1118-1122.
Rueda A, Alba E, Ribelles N, Sevilla I, Ruiz I, Miramon J.

9. Cardiotoxicidad y quimioterapia de intensificación.
Llamas P., Provencio M., Rubio A., Cabrera R., Fernández MN. Sangre, Volumen 40, número 1, 76, Febrero 1995.

10. Infusional chemotherapy (EPOCH) in patients with refractory or relapsed lymphoma. Am J Clin Oncol 1995; 18(1):44-46
Carrión JR, García Arroyo FR, Salinas P.

11. Intensive chemotherapy with support of peripheral hematopoietic progenitor cells, mobilized with high-dose cyclophosphamide and G-CSF: fast hematologic recovery. Rev Clin Esp 1995, 195: 83-88.
Sola C, Mendoza L, Amill B, Mesia R, Rueda A, Alonso MC, et al.

12. CHOP chemotherapy of intermediate and high-grade non-Hodgkin’s lymphoma. Acta Oncologica, 1994; 33: 935-939.
Llanos M, Tabernero JM, Brunet J, Amenedo M, Pallarés C, De Andrés L, López JJ.

13. Linfoma de células grandes primario de tiroides. A propósito de 6 casos tratados con quimioterapia.
Med Clin (Barc) 1994; 103:136-139
García Arroyo R, Carrión Galindo R, Arranz Arija JA, González San Segundo C, Martin Fragueiro L, Flores Sañudo E.

14. Primary renal lymphoma: Report of 3 cases and review of the literature. Am J Nephrol 1994;14:148-153
Arranz Arija JA, Carrión JR, García FR et al.

15. Neoplasias linfoides en el SIDA. Revisiones en Cáncer 1994; Vol 7(5):136-140
García Arroyo FR.

16. Tumores postrasplante. Neoplasia 1992; 9(2):57-60
García Arroyo FR, Carrión Galindo JR.

17. Recidiva de una enfermedad de Hodgkin después de 20 años. Med Clin 1992; 99:237
García Arroyo R, Flores Sañudo E, Carrión Galindo R, Menárguez Palanca J.

18. Glomerulopatía asociada a micosis fungoide. Nefrología 1990;10:448-449
García Arroyo FR.

X CURSO GOTEL

Buscar por fecha

Buscar por categoría